| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Kathryn Jean Boor is Director at SRPT, with reported holdings spanning 2 companies. Kathryn Jean Boor's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $490K at current prices.
Kathryn Jean Boor's largest disclosed position is in SRPT as Director, worth about $466K. The SRPT filings lean toward selling, a net 2,397 shares.
Kathryn Jean Boor has 13 Form 4 filings on record from March 2021 to June 2026, across 2 companies: Director at Sarepta Therapeutics (SRPT), 2022–2026; Director at International Flavors & Fragrances (IFF), 2021–2025.
The 21 reported transactions were 11 option or other derivative awards, 5 stock awards, 2 open-market sales and 2 dispositions back to the company, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $299K.
The largest open-market sale was 1,636 shares of SRPT at an average $125.55 on December 5, 2024, about $205K. Twelve months later SRPT was down 82%.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.